# A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

> **NCT02643303** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 58 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Breast Cancer
- Sarcoma
- Merkel Cell Carcinoma
- Cutaneous T-Cell Lymphoma
- Melanoma
- Renal Cancer
- Bladder Cancer
- Prostate Cancer
- Testicular Cancer
- Solid Tumor

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Poly-ICLC

## Key facts

- **NCT ID:** NCT02643303
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-28
- **Primary completion:** 2022-02-23
- **Final completion:** 2022-02-23
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2022-12-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02643303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02643303, "A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02643303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*